Current guidelines define the standard of care for patients after myocardial infarction (MI),
with particular focus on patients with significant ventricular dysfunction. Inherent in these …

The pharmacologic management of the patient post myocardial infarction (MI) aims to
achieve several goals. Chief among these is to prevent subsequent events, which include …

Treatment of acute myocardial infarction (MI) has been advanced considerably in the past
20 years with the advent of acute reperfusion strategies such as thrombolytic therapy or …

β-Blockers reduce cardiovascular death and reinfarction in patients with a history of
myocardial infarction (MI), and angiotensin-converting enzyme (ACE) inhibitors provide an …

The use of pharmacologic agents for the secondary prevention of sudden and non-sudden
death and recurrent myocardial infarction (MI) in patients who survive an acute MI has …

Sudden cardiac death (SCD) is still a major public health issue with an estimated annual
incidence ranging from 184,000 to> 400,000 per year. The ACC/AHA/ESC 2006 guidelines …

Following acute myocardial infarction, patients are at increased risk of developing heart
failure, which is more prevalent in those with reduced ventricular systolic function. Activation …

Modern treatment of acute myocardial infarction (AMI), including thrombolysis and early
interventional strategies, has reduced mortality rates but increased the number of patients …

Over 50 percent of deaths in patients who survive an acute myocardial infarction are due to
fatal ventricular tachyarrhythmias. Patients who survive an episode of sustained ventricular …

~ espite significant improvement in primary prevention and management, acute myocardial
infarction remains a major public health problem in the United States and most industrial …